Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ATHA vs IRD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATHA Captures Overall Composite Edge (56.2 HOLD vs 39.9 SELL), While IRD Leads 3–2 on Growth & Valuation Pillars

ATHA Overall Winner 6-Pillar Tally: ATHA 2 – 3 IRD (1 Tie) Matrix Metrics: ATHA 5 – 4 IRD

As of Nov 16, 2026, Athira Pharma, Inc. (ATHA) captures the overall head-to-head institutional edge over Opus Genetics, Inc. (IRD) on higher Unified Composite conviction (56.2/100 HOLD vs. 39.9/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while IRD wins 3–2 across the 6-pillar growth and valuation breakdown. ATHA trades at $6.75 (N/M Forward P/E, 0.0% operating margin) versus IRD at $3.94 (12.0x Forward P/E, -777.7% operating margin).

  • Growth vs. Quality Trade-Off: ATHA earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. IRD 39.9/100 SELL) and 6.17β · 241% Vol risk profile, whereas IRD leads top-line expansion (-63.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ATHA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IRD is in a Breakdown options structure phase (RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATHA vs IRD
ATHA NASDAQ Head-to-Head Winner
Athira Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.75
-6.12% 1D
Market Cap $26.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 6.17β · 241% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (23.0% over 20 days), RSI 57
RSI-14: 56.6 · SMA20: $6.36 · SMA50: $5.14
IRD NASDAQ
Opus Genetics, Inc. Common Stock
Pharmaceutical Preparations
$3.94
-1.01% 1D
Market Cap $392.4M
TTM Revenue $7.9M
Forward P/E 12.0x
Beta / 30D Vol 1.47β · 76% Vol
Unified Composite Score
39.9 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.6 · SMA20: $3.90 · SMA50: $4.47

6-Pillar Scorecard Institutional Category Breakdown (ATHA 2 – 3 IRD)

Columns: Metric · ATHA · IRD
1. Valuation Multiples IRD
Forward P/E N/M 12.0x
Trailing P/E N/M 12.0x
PEG Ratio N/M N/M
EV / Revenue N/M 42.9x
2. Growth & Scale IRD
Revenue Growth (YoY) +0.0% -63.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $7.9M
Market Cap $26.6M $392.4M
3. Profitability & Quality ATHA
Gross Margin N/A N/A
Operating Margin 0.0% -777.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -89.4% -615.6%
4. Balance Sheet & Cash Flow IRD
Cash Generation (TTM) N/A -$49M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.79 Book/Sh · -89.4% ROE $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATHA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 123.1% (12th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATHA (5) vs IRD (4)
Institutional Metric ATHA IRD Criterion Row Edge
Market Capitalization
Scale
$26.6M $392.4M Larger Scale IRD
Trailing P/E Ratio
Valuation
N/M 12.0x Lower Multiple IRD
Forward P/E Ratio
Valuation
N/M 12.0x Lower Multiple IRD
Revenue Growth (YoY)
Growth
+0.0% -63.1% Higher Growth ATHA
Operating Margin (TTM)
Profitability
0.0% -777.7% Higher Margin ATHA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-89.4% -615.6% Higher ROE ATHA
52-Week Range Position
Momentum
80% ($0–$8) 42% ($2–$7) Stronger Trend ATHA
Beta / 30D Volatility
Risk Regime
6.17β · 241% Vol 1.47β · 76% Vol Lower Realized Risk IRD
Unified Institutional Score
Composite Signal
56.2 / 100 (HOLD) 39.9 / 100 (SELL) Higher Composite ATHA
Trailing 12M Revenue (USD)
Operating Scale
N/A $7.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 42.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($6.79 Book/Sh · -89.4% ROE) -$49M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATHA +94.65 pp
ATHA: +73.75% · IRD: -20.9%
3M Horizon ATHA +39.45 pp
ATHA: +43.77% · IRD: +4.32%
6M Horizon ATHA +39.45 pp
ATHA: +43.77% · IRD: +4.32%
1Y Horizon ATHA +39.45 pp
ATHA: +43.77% · IRD: +4.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATHA vs IRD. Trailing 12-month operating profitability (ATHA 0.0% vs IRD -777.7%) and valuation multiples (ATHA N/M vs IRD 12.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ATHA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-89.4% · N/M
IRD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.9M
Gross MarginN/A
Op. Margin-777.7%
ROE / Fwd P/E-615.6% · 12.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATHA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATHA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRD BREAKDOWN
47d in phase · OBV NEUTRAL
Current IV 123.1%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IRD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATHA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $26.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IRD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $392.4M market capitalization and -777.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATHA vs IRD Key Questions & Quantitative Answers

As of Nov 16, 2026, Athira Pharma, Inc. (ATHA) captures the overall head-to-head institutional edge over Opus Genetics, Inc. (IRD) on higher Unified Composite conviction (56.2/100 HOLD vs. 39.9/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while IRD wins 3–2 across the 6-pillar growth and valuation breakdown. ATHA trades at $6.75 (N/M Forward P/E, 0.0% operating margin) versus IRD at $3.94 (12.0x Forward P/E, -777.7% operating margin). Growth vs. Quality Trade-Off: ATHA earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. IRD 39.9/100 SELL) and 6.17β · 241% Vol risk profile, whereas IRD leads top-line expansion (-63.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ATHA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IRD is in a Breakdown options structure phase (RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRD leads the Growth & Scale pillar: ATHA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IRD at -63.1% YoY revenue growth and +0.0% YoY earnings growth on $7.9M TTM revenue (N/A gross margin, -777.7% operating margin). On trailing 12-month operating scale, ATHA generates N/A in USD-normalized revenue versus $7.9M for IRD. In operating R&D and SG&A reinvestment, ATHA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IRD.

IRD screens cheaper on headline valuation multiples. ATHA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IRD trades at 12.0x Forward P/E, 12.0x Trailing P/E, N/M PEG, and 42.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATHA (-89.4% ROE) versus IRD (-615.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ATHA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.17β · 241% Vol realized risk). By comparison, IRD carries 123.1% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.